512. Deputy Ken O'Flynn asked the Minister for Health when she expects to make a decision on the report prepared by the expert group established by the HSE to examine the implications of the final review (details supplied) for gender-related healthcare services in Ireland; whether she has received and reviewed that report; whether any recommendations within it relate to safeguarding, clinical standards, or risk-mitig…
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn .
3,835 questions match, newest first.
513. Deputy Ken O'Flynn asked the Minister for Health the way in which she can defend the development or revision of national policy and models of care for gender identity services for children and young people in circumstances where the Health Service Executive has confirmed that neither her Department or the HSE has any policy governing the collection, verification, or publication of data on referrals, diagnoses, c…
514. Deputy Ken O'Flynn asked the Minister for Health the way in which she satisfies herself that public funds are being spent in a manner that meets basic standards of governance, safeguarding, and accountability (details supplied); and whether she accepts that reliance on financial audit alone does not constitute effective oversight. [9969/26]
848. Deputy Ken O'Flynn asked the Minister for Health the criteria used by the Health Service Executive to define and measure “success” in respect of outcomes arising from elective surgical procedures performed in public hospitals; and if she will make a statement on the matter. [16536/26]
849. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive maintains a comprehensive national record of mortality and morbidity data associated with elective surgical procedures carried out within the public health system; the format in which such data are collected and reported; and if she will make a statement on the matter. [16537/26]
850. Deputy Ken O'Flynn asked the Minister for Health the formal policies, protocols, or governance frameworks in place within the Health Service Executive governing the management and remediation of complications arising from elective surgical procedures performed in Ireland, including the funding and oversight arrangements for remedial treatment; and if she will make a statement on the matter. [16538/26]
880. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken or commissioned any cost-effectiveness analysis comparing high-dose influenza vaccines with standard dose influenza vaccines for adults aged 65 years and over for the 2026/2027 influenza season; if so, the date on which that analysis was completed; whether it informed procurement planning for that season; and if she will make …
881. Deputy Ken O'Flynn asked the Minister for Health whether her Department has formally requested the National Immunisation Advisory Committee to review high-dose influenza vaccines since 1 January 2025; if so, the date of that request; whether a written record of the request exists; and whether any further review is currently under consideration. [16703/26]
882. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives regular reports from the Health Service Executive on the number, duration of vacancy, and disposal status of residential properties owned by the HSE; the frequency of such reporting; and whether any performance indicators apply to the timely disposal of surplus residential assets. [16750/26]
883. Deputy Ken O'Flynn asked the Minister for Health whether any target timelines exist, at Departmental or HSE level, for the disposal of residential properties deemed surplus to requirements; if not, whether she intends to introduce such timelines in light of properties vacant for periods exceeding ten years. [16751/26]
884. Deputy Ken O'Flynn asked the Minister for Health whether her Department requires the HSE to centrally record and report the annual holding costs associated with vacant residential properties, including insurance, security, and maintenance; and if not, whether she considers this consistent with public financial management best practice. [16752/26]
885. Deputy Ken O'Flynn asked the Minister for Health whether the Department has conducted, since 2020, any review of the HSE Protocol for the Acquisition and Disposal of Property as published in 2022, with particular regard to disposal timelines and value-for-money safeguards; and if she will provide details of any such review. [16753/26]
917. Deputy Ken O'Flynn asked the Minister for Health the date on which the review of the medicines reimbursement process, as committed to in the Programme for Government, will commence; whether terms of reference has been agreed; whether those terms will explicitly include the assessment and reimbursement framework for orphan medicines; when the review is expected to conclude; and if she will make a statement on the…
918. Deputy Ken O'Flynn asked the Minister for Health in light of Rare Disease Day taking place on 28 February, if she will commit to introducing an early access scheme in Ireland for people living with rare diseases to access EMA-approved orphan medicines; if such an early access scheme will include orphan medicines products licenced for non-oncology conditions; and if she will make a statement on the matter. [16944…
919. Deputy Ken O'Flynn asked the Minister for Health if the Oversight Implementation Group for the National Rare Disease Strategy has been established, given that the strategy was published in August 2025; and if she will make a statement on the matter. [16945/26]
934. Deputy Ken O'Flynn asked the Minister for Health her plans to commence a review of the reimbursement process, as committed to in the Programme for Government; whether such a review will specifically include the way in which orphan medicines are assessed and reimbursed; and if she will make a statement on the matter. [16987/26]
935. Deputy Ken O'Flynn asked the Minister for Health in light of Rare Disease Day taking place on 28 February 2026, if she will commit to introducing an early access scheme in Ireland for people living with rare diseases to access EMA-approved orphan medicines; if such an early access scheme will include orphan medicines products licenced for non-oncology conditions; and if she will make a statement on the matter. […
510. Deputy Ken O'Flynn asked the Minister for Health the incremental cost-effectiveness ratio, cost per QALY gained, time horizon applied, and discount rate used in the full health technology assessments conducted by the National Centre for Pharmacoeconomics in respect of tirzepatide for type 2 diabetes mellitus and weight management; and whether lifetime modelling assumptions were applied in either assessment. [158…
511. Deputy Ken O'Flynn asked the Minister for Health whether the health technology assessments conducted in respect of tirzepatide included modelling of downstream healthcare cost offsets arising from reductions in incidence of type 2 diabetes; cardiovascular events; hospital admissions; and obesity-related complications; and to provide the percentage reductions assumed in each case within the base-case analysis. [1…
512. Deputy Ken O'Flynn asked the Minister for Health the projected gross and net annual budget impact, and five-year cumulative budget impact, of reimbursement of tirzepatide for weight management under the current eligibility criteria outlined by the HSE; and the estimated eligible patient population used in the budget impact model. [15813/26]
513. Deputy Ken O'Flynn asked the Minister for Health whether one-way or probabilistic sensitivity analyses were conducted as part of the pharmacoeconomic evaluations of tirzepatide and semaglutide; and if so, the key variables identified as having the greatest impact on cost-effectiveness outcomes. [15814/26]
514. Deputy Ken O'Flynn asked the Minister for Health the reasons for the duration between commissioning and completion of the full health technology assessment of tirzepatide for type 2 diabetes; and whether her Department has conducted any review of timelines in the medicines assessment process since 2023. [15815/26]
518. Deputy Ken O'Flynn asked the Minister for Health whether the provision of direct Exchequer funding by her Department to any non-statutory body is conditional upon the recipient maintaining a formally adopted safeguarding policy; a designated safeguarding officer; written mandatory reporting procedures in respect of safeguarding concerns; compliance with obligations under the Children First Act 2015 where applica…
519. Deputy Ken O'Flynn asked the Minister for Health whether her Department maintains a central register or consolidated oversight framework identifying all non-statutory bodies in receipt of direct Exchequer funding; whether that register records safeguarding compliance status, including the existence of safeguarding policies, designated safeguarding officers and reporting procedures; whether her Department require…
520. Deputy Ken O'Flynn asked the Minister for Health whether she has received the completed report of the expert clinical group examining the implications for Ireland of the Cass Review; on what date it was received by her Department or the HSE CEO; whether she has requested a copy; whether she intends to publish the report in full; if not, the statutory or policy basis for withholding publication; and if she will m…